Form 8-K - Current report:
SEC Accession No. 0000950170-25-071169
Filing Date
2025-05-14
Accepted
2025-05-14 13:49:07
Documents
16
Period of Report
2025-05-14
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K neog-20250514.htm   iXBRL 8-K 41399
2 EX-99.1 neog-ex99_1.htm EX-99.1 7538
3 GRAPHIC neog-ex99_1s1.jpg GRAPHIC 463714
4 GRAPHIC neog-ex99_1s2.jpg GRAPHIC 589241
5 GRAPHIC neog-ex99_1s3.jpg GRAPHIC 332322
6 GRAPHIC neog-ex99_1s4.jpg GRAPHIC 516382
  Complete submission text file 0000950170-25-071169.txt   2784758

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT neog-20250514.xsd EX-101.SCH 25023
18 EXTRACTED XBRL INSTANCE DOCUMENT neog-20250514_htm.xml XML 4730
Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: 8-K | Act: 34 | File No.: 000-17988 | Film No.: 25944338
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)